Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Annals of Neurology

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.410420511PMID 9392574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

  2004cited by this paper
• Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations

  1997cited by this paper
• Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

  1996cited by this paper
• Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.

  1996cited by this paper
• Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations

  1996cited by this paper
• A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.

  1994cited by this paper
• A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

  1994cited by this paper
• Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

  1994cited by this paper
• Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

  1994cited by this paper
• Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients

  1993cited by this paper
• Quantification of neurologic deficit

  1990cited by this paper
• Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.

  1989cited by this paper
• Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.

  1988cited by this paper
• Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

  1988cited by this paper
• Estimation of the Box Correction for Degrees of Freedom from Sample Data in Randomized Block and Split-Plot Designs

  1976cited by this paper
• Parkinsonism

  1967cited by this paper

• Treatment strategies for motor fluctuations in Parkinson’s disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America

  2025influential citation
• Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.

  2025cites this paper
• Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

  2025cites this paper
• Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis

  2024cites this paper
• The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson’s Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On

  2024cites this paper
• Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

  2023influential citation
• Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs

  2023cites this paper
• Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease

  2023cites this paper
• Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment

  2023cites this paper
• Catechol‐O‐methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease

  2023cites this paper
• COMT Inhibitors in the Management of Parkinson’s Disease

  2022cites this paper
• Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects

  2022cites this paper
• Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy

  2022cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• The Past, Present, and Future of Parkinson's Disease Treatment

  2020cites this paper
• Opicapone: A third generation COMT inhibitor

  2020cites this paper
• Parkinsonian Drugs: Guidelines for Japan

  2020cites this paper
• Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease

  2020cites this paper
• Medical Management and Prevention of Motor Complications in Parkinson’s Disease

  2020cites this paper
• On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease

  2020influential citation
• Definition and Classification of Parkinsonian Drugs

  2019cites this paper
• Treatment of Parkinson’s Disease: Early, Late, and Combined

  2019cites this paper
• Parkinson's disease: Diagnosis and appreciation of comorbidities.

  2019cites this paper
• Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial

  2019cites this paper
• Complications of levodopa therapy in Parkinson’s disease

  2019cites this paper
• Non-human primate models of PD to test novel therapies

  2018cites this paper
• Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics

  2018cites this paper
• Medical and surgical management of advanced Parkinson's disease

  2018cites this paper
• In this issue

  2018cites this paper
• Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation

  2018cites this paper
• Adverse event reporting in clinical trials in Parkinson's Disease: Time for change

  2018cites this paper
• Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review

  2018cites this paper
• Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease

  2018cites this paper
• Long-term ambulatory assessment of motor symptoms in movement disorders: a best-evidence review

  2018cites this paper
• Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

  2017cites this paper
• Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson’s Disease with Motor Fluctuation: A Systematic Meta-Analysis

  2017cites this paper
• Movement Disorders Curricula

  2017influential citation
• Opicapone for the treatment of Parkinson’s disease

  2017cites this paper
• Old and new challenges in Parkinson's disease therapeutics

  2017influential citation
• MEETING REPORTER

  2017cites this paper
• Treatment for Dementia: Learning from Breakthroughs for Other Conditions.

  2016cites this paper
• A review of current and novel levodopa formulations for the treatment of Parkinson's disease.

  2016cites this paper
• Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

  2015cites this paper
• Treatment strategies in early and advanced Parkinson disease.

  2015cites this paper
• Time to change the blind men and the elephant approach to Parkinson disease?

  2015cites this paper
• Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off

  2015cites this paper
• Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease

  2015cites this paper
• Improving l‐dopa therapy: The development of enzyme inhibitors

  2015cites this paper
• The efficacy of Levodopa+DDC inhibitor+Entacapone versus Levodopa+DDC inhibitor+Placebo in Parkinson's disease: an intervention review

  2015cites this paper
• Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease

  2015cites this paper
• Towards the Development of a Wearable Tremor Suppression Glove

  2015cites this paper
• Pooled analysis of phase III with entacapone in Parkinson's disease

  2014cites this paper
• UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

  2014cites this paper
• Specificity and sensibility of 9-Itens Wearing-off Questionnaire in Brazilian Parkinson disease patient sample.

  2014cites this paper
• Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.

  2014cites this paper
• Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial

  2014cites this paper
• Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on Levodopa/Carbidopa/Entacapone for Treatment of Levodopa-Associated Motor Complications

  2013cites this paper
• Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature

  2013cites this paper
• The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.

  2013cites this paper
• Treatment of Parkinson’s disease in the advanced stage

  2013cites this paper
• Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments

  2013cites this paper
• Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.

  2012cites this paper
• Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone

  2012cites this paper
• Cost Effectiveness of Treatment of Parkinson’s Disease with Entacapone in the United States

  2012cites this paper
• Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials

  2012cites this paper
• Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.

  2012cites this paper
• Updates in the medical management of Parkinson disease

  2012cites this paper
• Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone

  2012cites this paper
• Association of adverse effects with monoamine oxidase type B inhibitor and catechol-o-methyl transferase inhibitor combination therapy in Parkinson’s disease patients

  2012cites this paper
• Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease

  2012cites this paper
• Economic and Health-Related Quality of Life Considerations of New Therapies in Parkinson’s Disease

  2012cites this paper
• Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease

  2012cites this paper
• The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations

  2012cites this paper
• An approach to the continuous dopaminergic stimulation in Parkinson's disease.

  2012cites this paper
• A behavioural evaluation of the potential of nNOS inhibitors to control dyskinesia in animal models of Parkinson's disease

  2012influential citation
• A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.

  2011cites this paper
• Pathological considerations in the treatment of Parkinson's disease: more than just a wiring diagram.

  2011cites this paper
• Motor Complications in Parkinson's Disease

  2011cites this paper
• Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off

  2011influential citation
• Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease

  2011influential citation
• Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.

  2011cites this paper
• No correlation between COMT genotype and entacapone benefi ts in Parkinson ’ s disease

  2011cites this paper
• Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

  2011cites this paper
• Motor fluctuations and dyskinesias (diagnosis and management)

  2011cites this paper
• The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease

  2010influential citation
• Levodopa in Parkinson's disease: from the past to the future

  2010cites this paper
• UPDATE ON THE MEDICAL MANAGEMENT OF PARKINSON DISEASE

  2010cites this paper
• Entacapone

  2010cites this paper
• [Treatment of mental disorders in patients with Parkinson's disease].

  2010cites this paper
• [Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].

  2010cites this paper
• Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease

  2010cites this paper
• Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

  2010cites this paper
• Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study

  2010influential citation
• Parkinson's disease: 10 years of progress, 1997–2007

  2010cites this paper
• Parkinson’s Disease and Motor Fluctuations

  2010cites this paper
• The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease

  2010cites this paper
• Therapie psychischer Störungen bei Morbus Parkinson

  2010cites this paper
• Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

  2010cites this paper
• Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study

  2010cites this paper
• [Continuous dopaminergic stimulation - clinical experience].

  2010cites this paper